Back to Search
Start Over
Designer broad-spectrum polyimidazolium antibiotics.
- Source :
-
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Dec 08; Vol. 117 (49), pp. 31376-31385. Date of Electronic Publication: 2020 Nov 23. - Publication Year :
- 2020
-
Abstract
- For a myriad of different reasons most antimicrobial peptides (AMPs) have failed to reach clinical application. Different AMPs have different shortcomings including but not limited to toxicity issues, potency, limited spectrum of activity, or reduced activity in situ. We synthesized several cationic peptide mimics, main-chain cationic polyimidazoliums (PIMs), and discovered that, although select PIMs show little acute mammalian cell toxicity, they are potent broad-spectrum antibiotics with activity against even pan-antibiotic-resistant gram-positive and gram-negative bacteria, and mycobacteria. We selected PIM1, a particularly potent PIM, for mechanistic studies. Our experiments indicate PIM1 binds bacterial cell membranes by hydrophobic and electrostatic interactions, enters cells, and ultimately kills bacteria. Unlike cationic AMPs, such as colistin (CST), PIM1 does not permeabilize cell membranes. We show that a membrane electric potential is required for PIM1 activity. In laboratory evolution experiments with the gram-positive Staphylococcus aureus we obtained PIM1-resistant isolates most of which had menaquinone mutations, and we found that a site-directed menaquinone mutation also conferred PIM1 resistance. In similar experiments with the gram-negative pathogen Pseudomonas aeruginosa, PIM1-resistant mutants did not emerge. Although PIM1 was efficacious as a topical agent, intraperitoneal administration of PIM1 in mice showed some toxicity. We synthesized a PIM1 derivative, PIM1D, which is less hydrophobic than PIM1. PIM1D did not show evidence of toxicity but retained antibacterial activity and showed efficacy in murine sepsis infections. Our evidence indicates the PIMs have potential as candidates for development of new drugs for treatment of pan-resistant bacterial infections.<br />Competing Interests: Competing interest statement: M.B.C.-P., P.T.H., W.Z., S.H.M., and B.L. are co-inventors in patent filings based on this paper.<br /> (Copyright © 2020 the Author(s). Published by PNAS.)
- Subjects :
- Animals
Anti-Bacterial Agents chemistry
Anti-Bacterial Agents therapeutic use
Cell Death drug effects
Cell Line
Cell Membrane drug effects
Designer Drugs chemistry
Designer Drugs therapeutic use
Humans
Hydrophobic and Hydrophilic Interactions
Imidazoles chemistry
Imidazoles therapeutic use
Membrane Potentials drug effects
Mice
Microbial Sensitivity Tests
Microbial Viability drug effects
Pseudomonas Infections drug therapy
Pseudomonas Infections microbiology
Pseudomonas Infections pathology
Pseudomonas aeruginosa drug effects
Sepsis drug therapy
Sepsis prevention & control
Skin drug effects
Skin microbiology
Skin pathology
Anti-Bacterial Agents pharmacology
Designer Drugs pharmacology
Imidazoles pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1091-6490
- Volume :
- 117
- Issue :
- 49
- Database :
- MEDLINE
- Journal :
- Proceedings of the National Academy of Sciences of the United States of America
- Publication Type :
- Academic Journal
- Accession number :
- 33229526
- Full Text :
- https://doi.org/10.1073/pnas.2011024117